Alkhunaizi Lama, Almutairi Jawza A, Almanea Sarah H, Alzahuf Shuruq M, Fehaid Mohammed, Alharthi Abdulaziz, Alhebs Tameem, Alshuqayfi Sarah M, Alotaibi Rana, Alharbi Meshari, Abdalwahab Zahra E, Aloqaybi Abeer, Talebi Sarah H, Kharaba Ayman M
College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAU.
Ophthalmology, King Khaled Hospital, Al Majmaah, SAU.
Cureus. 2024 Feb 1;16(2):e53412. doi: 10.7759/cureus.53412. eCollection 2024 Feb.
The COVID-19 pandemic has presented significant challenges in clinical management, and intensive care units (ICUs) worldwide have become epicenters of high-stakes treatment decisions. Among these, corticosteroid therapy has risen as a pivotal, yet controversial, treatment modality. In Saudi Arabia, where unique demographic and health system characteristics intersect, understanding the specific effects of corticosteroids on ICU patient outcomes is not just critical but a pressing necessity in tailoring effective COVID-19 management strategies.
This study aims to elucidate the effects of corticosteroid therapy on the outcomes of severe COVID-19 patients in Saudi Arabian ICUs, providing critical insights into treatment efficacy and guiding future clinical practices.
In this cohort study, we meticulously reviewed the medical records of 1085 severe COVID-19 patients admitted to Saudi Arabian ICUs. Our analysis focused on demographic details, ICU outcomes, and the extent and implications of corticosteroid therapy. The study employed comprehensive methods for data collection, evaluation criteria, and statistical analysis, ensuring a thorough understanding of the impact of corticosteroids in this context.
The study encompassed 1085 patients, predominantly male (74.5%, N=806), with an average age of 56 and a mean BMI of 30.07. A significant portion (72.3%, N=784) received corticosteroid therapy. These patients generally experienced longer ICU (mean 23 days) and hospital stays (mean 16 days), along with higher rates of microbiological cure (72.3%, N=648) and increased ICU discharge likelihood. Conversely, corticosteroid recipients showed higher mortality rates at ICU discharge. The statistical analysis confirmed the significance of these findings, reinforcing their importance in managing COVID-19 in ICUs.
The research highlights the intricate dynamics of corticosteroid use in treating severe COVID-19 cases in ICUs. While associated with prolonged ICU stays and increased mortality, corticosteroids also correlate with higher microbiological cure rates and discharge likelihood. These insights call for careful deliberation in applying corticosteroid therapy, with implications for enhancing clinical protocols and guiding future research in severe COVID-19 treatment.
新型冠状病毒肺炎(COVID-19)大流行给临床管理带来了重大挑战,全球重症监护病房(ICU)已成为高风险治疗决策的中心。其中,皮质类固醇疗法已成为一种关键但有争议的治疗方式。在沙特阿拉伯,独特的人口统计学和卫生系统特征相互交织,了解皮质类固醇对ICU患者预后的具体影响不仅至关重要,而且对于制定有效的COVID-19管理策略迫在眉睫。
本研究旨在阐明皮质类固醇疗法对沙特阿拉伯ICU中重症COVID-19患者预后的影响,为治疗效果提供关键见解并指导未来临床实践。
在这项队列研究中,我们仔细查阅了1085例入住沙特阿拉伯ICU的重症COVID-19患者的病历。我们的分析集中在人口统计学细节、ICU预后以及皮质类固醇疗法的程度和影响。该研究采用了全面的数据收集、评估标准和统计分析方法,以确保全面了解皮质类固醇在这种情况下的影响。
该研究涵盖1085例患者,主要为男性(74.5%,n = 806),平均年龄56岁,平均体重指数为30.07。很大一部分患者(72.3%,n = 784)接受了皮质类固醇疗法。这些患者通常在ICU的住院时间较长(平均23天),住院时间也较长(平均16天),微生物学治愈率较高(72.3%,n = 648),从ICU出院的可能性增加。相反,接受皮质类固醇治疗的患者在ICU出院时死亡率较高。统计分析证实了这些发现的显著性,强化了它们在ICU中管理COVID-19的重要性。
该研究突出了在ICU中治疗重症COVID-19病例时使用皮质类固醇的复杂动态。虽然与ICU住院时间延长和死亡率增加有关,但皮质类固醇也与较高的微生物学治愈率和出院可能性相关。这些见解要求在应用皮质类固醇疗法时进行仔细考虑,这对加强临床方案和指导重症COVID-19治疗的未来研究具有重要意义。